CA2295807A1 - Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales - Google Patents

Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales Download PDF

Info

Publication number
CA2295807A1
CA2295807A1 CA002295807A CA2295807A CA2295807A1 CA 2295807 A1 CA2295807 A1 CA 2295807A1 CA 002295807 A CA002295807 A CA 002295807A CA 2295807 A CA2295807 A CA 2295807A CA 2295807 A1 CA2295807 A1 CA 2295807A1
Authority
CA
Canada
Prior art keywords
compound
adhesions
retinoid
surgical
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295807A
Other languages
English (en)
Inventor
Xina Nair
Fred Christopher Zusi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2295807A1 publication Critical patent/CA2295807A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne certains dérivés rétinoïdes. La plupart ou la totalité d'entre eux tiennent lieu d'agonistes rétinoïdes sélectifs vis-à-vis des récepteurs RXR et, en tant que tels, ils ont démontré leur utilité dans la prévention ou la diminution de l'importance du phénomène de la formation des adhérences résultant d'interventions chirurgicales.
CA002295807A 1997-07-29 1998-07-28 Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales Abandoned CA2295807A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5401797P 1997-07-29 1997-07-29
US60/054,017 1997-07-29
PCT/US1998/015625 WO1999006036A1 (fr) 1997-07-29 1998-07-28 Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales

Publications (1)

Publication Number Publication Date
CA2295807A1 true CA2295807A1 (fr) 1999-02-11

Family

ID=21988221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295807A Abandoned CA2295807A1 (fr) 1997-07-29 1998-07-28 Utilisation d'agonistes selectifs vis-a-vis des recepteurs rxr pour eviter les adherences resultant d'interventions chirurgicales

Country Status (5)

Country Link
EP (1) EP1003493A4 (fr)
JP (1) JP2001511445A (fr)
AU (1) AU733236B2 (fr)
CA (1) CA2295807A1 (fr)
WO (1) WO1999006036A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
CN102058571B (zh) * 2005-09-09 2012-09-19 有限会社肯菲思 4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸在制备用于预防及/或治疗肠疾病的药物中的应用
JP5055971B2 (ja) 2006-11-16 2012-10-24 株式会社ニコン 表面処理方法及び表面処理装置、露光方法及び露光装置、並びにデバイス製造方法
JP2008179570A (ja) * 2007-01-25 2008-08-07 R&R Inc 内臓癒着の予防及び／又は治療のための医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195716T1 (de) * 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
AU700706B2 (en) * 1992-11-25 1999-01-14 Ligand Pharmaceuticals, Inc. RXR homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same

Also Published As

Publication number Publication date
AU733236B2 (en) 2001-05-10
WO1999006036A1 (fr) 1999-02-11
EP1003493A1 (fr) 2000-05-31
AU8667098A (en) 1999-02-22
JP2001511445A (ja) 2001-08-14
EP1003493A4 (fr) 2002-03-27

Similar Documents

Publication Publication Date Title
FI88025C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva vinylfenolderivat
US5434295A (en) Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US5837725A (en) Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
EP0747347B1 (fr) Dérivés de l'acide rétino-benzoique ayant une activité RAR-gamma-spécifique
JPH068263B2 (ja) 新規な４−ビニル安息香酸誘導体類、それらの製法及びそれらの治療剤及びリガントとしての用途
JP2943089B2 (ja) イソプレノイドホスホリパーゼ▲ａ２▼阻害剤およびそれを包含する製剤
HU193343B (en) Process for production of derivatives izoxalols
KR20000023626A (ko) 세포자멸사 유도 아다만틸 유도체 및 항암제로서의 그의 용도
JP2022524780A (ja) カンナビノイド酸エステル組成物およびその使用
DE69631688T2 (de) Indanverbindungen mit relaxierender Wirkung auf die glatten Muskeln und/oder mit Mastzellen stabilisierender und/oder entzündungshemmender Wirkung
KR100466730B1 (ko) 신규한 선택적 레티노이드 작용물질
US3649679A (en) Substituted phenylalkanoic acid derivatives ii
AU733236B2 (en) Use of selective RXR agonists to prevent surgical adhesions
WO2005019162A1 (fr) Derives d'acide hydroxamique et leur methode de preparation
JP2000507223A (ja) 抗炎症剤としてのベンズアミドとニコチンアミドの組成物とその使用
HU191531B (en) Process for the production of /halogen-phenyl/-glyceride esters
US4459404A (en) Amides of retinoic acids with 5-amino tetrazole
AU665353B2 (en) Cholesterol-lowering tocopherol analogs
US3860722A (en) Hypolipidemic agents
BR0214241A (pt) Método para preparar uma composição compreendendo lipossomas contendo anestésico tópico e composição obtida
JPS60104084A (ja) ４Ｈ‐ベンゾ〔４，５〕シクロヘプタ〔１，２‐ｂ〕チオフエン誘導体
NZ311488A (en) Retinoids and methods of use of same
JPS6299329A (ja) 皮膚用抗炎症組成物
AU629290B2 (en) Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions
EP0176050A2 (fr) Esters d'acide vinylbenzyl phosphoriques, leur préparation et leur utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead